Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \< 75 years~* Type-2 diabetes~* Therapy resistant hypertension (by ABPM)~* Treatment with at least 3 antihypertensives~Exclusion Criteria:~* HbA1c \> 10.0~* BP \> 180/110 mmHg~* Secondary hypertension~* Intolerance to spironolactone~* Permanent treatment with nonsteroidal antiinflammatory drugs or systemic glucocorticoids~* Total cholesterol 10 mmol/l~* New York Heart Association class III and IV~* Pregnancy or planned pregnancy~* Psychiatric disease~* Malignant disease~* Insufficient adherence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- addition of spironolactone (Type: EXPERIMENTAL): spironolactone is added to previous antihypertensive treatment
- Placebo (Type: PLACEBO_COMPARATOR): Addition of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).